您好,欢迎访问中国农业科学院 机构知识库!

A Ferritin-Based Eg95 Nanoparticle Vaccine Adjuvanted with pCpG Eliciting Robust Immune Responses Against Cystic Echinococcosis in Mice Model

文献类型: 外文期刊

作者: Gao, Xintao 1 ; Zhu, Xizhou 2 ; Liu, Xingjian 1 ; Zhou, Chenghao 1 ; Shang, Yuting 1 ; Wu, Tong 1 ; Jia, Hong 3 ; Zhang, Zhifang 1 ; Li, Yinue 1 ; Xin, Ting 3 ;

作者机构: 1.Chinese Acad Agr Sci, Biotechnol Res Inst, Natl Key Lab Agr Microbiol, Beijing, Peoples R China

2.Chinese Acad Agr Sci, Bioprod Engn Ctr, Beijing, Peoples R China

3.Chinese Acad Agr Sci, Inst Anim Sci, Beijing, Peoples R China

关键词: cystic echinococcosis; vaccine; combination adjuvant; ferritin nanoparticle; CpG

期刊名称:INTERNATIONAL JOURNAL OF NANOMEDICINE ( 影响因子:6.5; 五年影响因子:7.7 )

ISSN: 1178-2013

年卷期: 2025 年 20 卷

页码:

收录情况: SCI

摘要: Introduction: Cystic echinococcosis (CE), a chronic disabling parasitic zoonosis, poses a great threat to public health and livestock production and causes huge economic losses globally. The commercial Quil-A-adjuvanted Eg95 vaccine was empirically effective for CE control; however, it is expensive and has side effects and insufficient immunity. Purpose: This study aimed to employ a novel adjuvant consisting of a delivery system and an immune potentiator and assess its adjuvanticity to Eg95 antigen, thereby developing a safe and cost-effective novel vaccine against the disease. Methods: A ferritin-based Eg95 nanoparticle antigen was prepared and then mixed with a plasmid containing the TLR9 agonist CpG to formulate a novel nanovaccine. The safety and efficacy of the vaccine were evaluated in vitro and in vivo. Results: The nanovaccine induced potent and enduring Eg95-specific humoral and cellular immune responses, as well as protective immunity-associated Th1 polarization supported by the higher ratios of IgG2a/IgG1 and IFN-gamma/IL-4. Meanwhile, this nanovaccines exhibited favorable safety and economic profiles. Conclusion: Our data demonstrated that the ferritin-CpG hybrid is a promising combination adjuvant to upgrade the traditional Quil-A and this combination adjuvant-based nanovaccine presents good potential as an alternative to the commercial one for practical CE control.

  • 相关文献
作者其他论文 更多>>